Anixa BiosciencesANIX
ANIX
About: Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
Employees: 5
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
425% more call options, than puts
Call options by funds: $126K | Put options by funds: $24K
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
42% more capital invested
Capital invested by funds: $12.4M [Q2] → $17.5M (+$5.15M) [Q3]
8% more funds holding
Funds holding: 52 [Q2] → 56 (+4) [Q3]
0.05% less ownership
Funds ownership: 17.46% [Q2] → 17.42% (-0.05%) [Q3]
31% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 13
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$7
190%
upside
Avg. target
$8.50
253%
upside
High target
$10
315%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 0 / 0 met price target | 315%upside $10 | Buy Maintained | 14 Jan 2025 |
HC Wainwright & Co. Yi Chen 62% 1-year accuracy 13 / 21 met price target | 190%upside $7 | Buy Reiterated | 19 Nov 2024 |
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10
SAN JOSE, Calif , Dec. 4, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced today that it will be participating in the iAccess Alpha Virtual Best Ideas Winter Conference 2024 being held on December 10th and 11th, 2024. Dr. Amit Kumar, CEO of Anixa, is scheduled to present on Tuesday, December 10 th at 2:00 p.m.
Neutral
PRNewsWire
1 month ago
Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
SAN JOSE, Calif. , Nov. 22, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset.
Neutral
PRNewsWire
1 month ago
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer.
Neutral
PRNewsWire
2 months ago
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025 SAN JOSE, Calif. , Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas.
Neutral
PRNewsWire
2 months ago
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif. , Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, will be made publicly available on the Company's website at 12:15pm CT on November 8, 2024.
Neutral
PRNewsWire
2 months ago
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
SAN JOSE, Calif. , Oct. 31, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its presentation at the Sidoti Micro-Cap Virtual Conference, taking place November 13-14, 2024.
Neutral
PRNewsWire
2 months ago
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas, from November 6-10, 2024.
Neutral
PRNewsWire
3 months ago
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif. , Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has administered the second dose of its CAR-T therapy to an individual patient.
Neutral
PRNewsWire
3 months ago
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development
SAN JOSE, Calif. , Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development.
Neutral
PRNewsWire
3 months ago
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
Amendment will allow a second dose of CAR-T therapy to suitable patients SAN JOSE, Calif. , Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it and partner Moffitt Cancer Center ("Moffitt") have submitted an amendment to the current protocol that governs its ongoing clinical trial utilizing a CAR-T therapy to treat ovarian cancer (NCT05316129).
Charts implemented using Lightweight Charts™